November 12–15
Copenhagen
Keeping pace with advances in value demonstration and AI
HEOR and market access are evolving, with big changes in HTA around the corner, acceleration in the use of RWE and increased reactions to cost-containment measures. We are contributing to conversations about how these changes affect value demonstration strategies. At Oxford PharmaGenesis, we are experts in advising on payer strategy, developing payer evidence and supporting payer evaluation. We understand differences in payer evidence needs, and we know how to create compelling value stories for our clients that achieve powerful results.
The rapid progress in the development of large language models has taken the world by storm and holds much potential in many areas of medicine. However, the stakes are high, so it is vital that their application be thought through carefully and responsibly. At Oxford PharmaGenesis, we take a measured approach to AI and combine it with a deep understanding of systematic reviews. This ensures that we always provide the highest-quality outcomes using the approach best suited to our clients’ needs.
Communications Team Leader – Value Demonstration
My team supports our clients across a wide range of value communications and has an interest in RWE and patient-centred research. I'm looking forward to attending ISPOR Europe 2023 and hearing the latest perspectives in HEOR.
Communications Team Leader – Value Demonstration
My team supports our clients across RWE, synthesis and communication. I am looking forward to hearing the latest perspectives in the field and joining discussions at ISPOR Europe 2023!
Scientific Director – Evidence Generation and Synthesis
I provide strategic and scientific oversight for evidence generation and synthesis projects at Oxford PharmaGenesis. I have a particular interest in systematic literature reviews supporting HTA submissions. I look forward to speaking with you at ISPOR Europe 2023!
Communications Director
I am the strategic lead for several teams with a focus on accessible communication and high-calibre research, supporting our clients to provide the evidence that payers need. I am presenting some of our new thinking around literature reviews at ISPOR Europe 2023 and I am excited to join discussions about how HTA is evolving to bring faster access to new treatments.
Communications Director – Value Demonstration
I provide strategic and scientific oversight to several teams who develop value communications and evidence for payers. I am interested in hearing discussions about EU HTA and understanding how we can support our clients with navigating this new process. I hope to speak with you at ISPOR Europe 2023.
Scientific Director – AI and Data Science
I lead AI and data science projects at Oxford PharmaGenesis. I have a particular interest in the potential of AI to ease the burden of systematic literature reviews. I look forward to speaking with you at ISPOR Europe 2023!
If you want to speak to one of our team members about how we can support you, please fill in the contact form below.
